Dr. Tomalia helps FDA scientists better understand nanotechnology and prepare for forthcoming FDA review of nanotechnology-based therapies

Dr. Donald Tomalia, the founder of Dendritic NanoTechnologies Inc. (DNT), is presenting today at a two-day workshop being held by the Federal Drug Administration. Dr. Tomalia will kick off today’s workshop with a presentation titled: “Dendrimer-Based Nanotechnology: Its Impact on Biology, Pharma Delivery, MRI Imaging and Polyvalent/Targeted Therapies.”

The FDA’s Center for Drug Evaluation and Research (CDER) is actively seeking to educate its scientists in this emerging science. In the near future, a significant number of submissions for nanotechnology products will need to be reviewed by FDA/CDER scientists. In order to be ready for these nanotechnology submissions, the FDA needs to ensure adequate education of its scientific reviewers in specific areas that might be unique to this field. Dr. Tomalia is playing a part in this educational process, and this is the second time he has presented to the FDA’s scientists.

As investment funding pours into nanotechnology, the sector is featuring prominently in the FDA’s monitoring of emerging sciences. The agency recently launched a website focused on nanotech (http://www.fda.gov/nanotechnology). It has also formed a Nanotechnology Interest Group that will meet quarterly to help coordinate regulatory efforts across its various research centers, including the CDER.

About DNT

Dendritic NanoTechnologies Inc. (DNT) is a technology company that is a leading developer and provider of advanced dendritic nanoscale polymers. Dendrimers are nanostructures with specific, precise and predictable physical properties that make them especially useful for pharmaceuticals, medical imaging, electronics, materials, and the mass commercial markets. DNT has a broad and comprehensive IP portfolio that comprises over 200 patents in 41 patent families—a unique level of IP concentration among nanotechnology companies—and has existing licensing agreements with established revenue streams for dendrimer technology. DNT’s business strategy is to establish dendrimer technology, through licensing agreements, as the preferred nanotechnology enabling platform from which to build value and generate revenue for DNT and its customers. DNT’s technology development is directed by Donald A. Tomalia Ph.D., the company’s president and chief technical officer. Dr. Tomalia had a 25-year management and senior scientist career with The Dow Chemical Company, has numerous commercial developments including Citrucel® (now marketed by GlaxoSmithKline) and cationic polymerization of 2-oxazolines, and is the inventor and originator of the term “dendrimers.” Incorporated in 2003, DNT is a U.S. company located in Mount Pleasant, Michigan. http://www.dnanotech.com.

Contact:

Tim Cox
Zing Public Relations
+1-650-369-7784 office
+1-650-888-6116 cell
tim@zingpr.com

Online ordering of STARBURST® dendrimers now available.
06-25-2008

First commercial product launch of Starpharma’s DNT Priostar® Dendrimers
- EMD Chemicals Inc. launches DNA Transfection Reagent Kit -
04-22-2008

Starpharma signs agreement with Unilever
04-07-2008

New Lower Pricing on STARBURST® PAMAM Dendrimers
02-26-2008

Oncologix Tech, Inc. and Dendritic Nanotechnologies, Inc. Resolve Leaching Issues with the Oncosphere Product
08-22-2007